In the context of aggressive diseases, KRAS is overexpressed in about 30% of all human cancers including 95% of pancreatic and 45% of colorectal and non-small-cell lung cancer (NSCLC) [5,6]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.